Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Age-stratified associations between severe mental illness, dementia, and ischemic stroke: findings from the PADRIS-PRESTO cohort

  • De Prisco, Michele
  • Oliva, Vincenzo
  • Sanchez-Valle, Raquel
  • Parellada, Eduard
  • Junque, Carme
  • Marti, Maria J.
  • Bortolozzi, Analía
  • Alberch, Jordi
  • Garrabou, Gloria
  • Sanchez-Vives, Maria V.
  • Giralt, Albert
  • Segura, Barbara
  • Lladó, Albert
  • Compta, Yaroslau
  • Radua, Joaquim
  • Vieta, Eduard
  • Hidalgo-Mazzei, Diego
  • Anmella, Gerard
People with severe mental illnesses (SMIs), including schizophrenia spectrum disorders (SSD), major depressive disorder (MDD), and bipolar disorder (BD), experience elevated rates of physical comorbidity and premature mortality. Dementia and ischemic stroke contribute substantially to this burden, yet age-specific patterns of these associations remain poorly characterized. To bridge this gap, we conducted a population-based cross-sectional study using the PADRIS-PRESTO cohort, integrating primary and specialized care records from the Catalan public health system (Spain). Adults with a lifetime SMI diagnosis were compared with controls without any psychiatric condition. Weighted age-stratified prevalence was calculated and logistic regression models estimated age-specific odds ratios (ORs) with 95% confidence intervals (CIs), adjusting for socioeconomic status and medical comorbidity burden. Among 694,086 participants, 176,870 had an SMI diagnosis. Dementia prevalence was 3.49% (range, 0.33% at ages 20-29 to 39.51% at 90-99 years) in SMIs and 0.36% (0.02%-17.7%) in controls. Ischemic stroke prevalence was 5.3% (0.22%-16.4%) in SMIs and 2.75% (0.08%-14.67%) in controls. The ORs between SMI and dementia were significant across all age groups, with the strongest association observed at younger ages (OR = 23.21, 95% CIs = 13.74-39.19 at 30-39 years). Elevated ORs for stroke persisted up to 70-79 years, peaking at 40-49 years (OR = 2.99, 95% CIs = 2.63-3.41). Patterns were consistent across SMI subtypes. These findings highlight the need for earlier and more systematic neurological and cardiometabolic screening and management within psychiatric care and support policies that recognize SMIs as risk factors for vascular diseases and dementia., Michele De Prisco is supported by the Translational Research Programme for Brain Disorders, IDIBAPS. Vincenzo Oliva thanks the support of the Spanish Ministry of Science, Innovation and Universities financed by the Instituto de Salud Carlos III (ISCIII) and co-financed by the European Social Fund+ (ESF+) (CM24/00143, MV25/00042). Carme Junque thanks the Spanish Ministry of Economy and Competitiveness (MINECO PID2020-114640GB-I00/ and PID2023-146932NB-I00 financed by MICIU/AEI/ 110.13039/5011000111033/FEDER, UE); Generalitat de Catalunya (SGR 2021SGR00801); María de Maeztu Unit of Excellence (Institute of Neurosciences, University of Barcelona) CEX2021001159-M, Ministry of Science and Innovation; and La Marato 202225-31358/U/2022. Analia Bortolozzi thanks the Spanish Ministry of Economy and Competitiveness (MCIU/AEI/FEDER, UE grant PID2022-141700OB-I00, MCIN/AEI/10.13039/501100011033); La Marató de TV3 Foundation 202207-30; and Caixa Research Health - HR25-00556. Jordi Alberch is supported by a grant from Ministerio de Ciencia e Innovación/AEI/https://doi.org/10.13039/501100011033/ and “FEDER” (PID2024-157024OB-I00). Gloria Garrabou is supported by The Catalan Government (2021-SGR-01423), and Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III (PI24/00428) and CIBERER, both initiatives of ISCIII and FEDER, co-funded by the European Union. Maria V. Sanchez-Vives is funded by the European Union (ERC, NEMESIS, project number 101071900). Albert Giralt is supported by a grant from Ministerio de Ciencia e Innovación/AEI/https://doi.org/10.13039/501100011033/ and “FEDER” (PID2020-119386RB-I00). Barbara Segura thanks the Spanish Ministry of Economy and Competitiveness (PID2023-146932NB-I00 financed by MICIU/AEI/ 110.13039/5011000111033/FEDER, UE); Generalitat de Catalunya (SGR 2021SGR00801); María de Maeztu Unit of Excellence (Institute of Neurosciences, University of Barcelona) CEX2021001159-M, Ministry of Science and Innovation; and La Marato 202225-31358/U/2022. Joaquim Radua thanks the support of the Spanish Ministry of Science, Innovation and Universities (CPII19/00009, PI22/00261, PI25/01463) integrated into the Plan Nacional de I + D+I and co-financed by the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) and the Instituto de Salud Carlos III; and the Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2021-SGR-01128). Eduard Vieta thanks the support of the Spanish Ministry of Science, Innovation and Universities (PI21/00787, PI24/00432) integrated into the Plan Nacional de I+D+I and co-financed by the Instituto de Salud Carlos III -Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); the Generalitat de Catalunya and Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2021 SGR 01128), CERCA Programme, Generalitat de Catalunya; La Marató-TV3 Foundation grants 202234-30; the European Union Horizon 2020 research and innovation program (H2020-EU.3.1.1. - Understanding health, wellbeing and disease, H2020-EU.3.1.3. Treating and managing disease: Grant 945151, HORIZON.2.1.1 - Health throughout the Life Course: Grant 101057454 and EIT Health (EDIT-B project). Diego Hidalgo-Mazzei gratefully acknowledges the support of the Spanish Ministry of Health, Instituto de Salud Carlos III (PI049759) and the Pons-Bartran Legacy grant 2024 (FCRB_IPB1_2024). Gerard Anmella thanks the support of the Spanish Ministry of Science, Innovation and Universities financed by the Instituto de Salud Carlos III (ISCIII) and co-financed by the European Social Fund+ (ESF+) (JR23/00050, MV22/00058, CM21/00017); the ISCIII (PI24/00584, PI24/01051, PI21/00340, PI21/00169); the Milken Family Foundation (PI046998); the Fundació Clínic per a la Recerca Biomèdica (FCRB) - Pons Bartan 2020 grant (PI04/6549), the Sociedad Española de Psiquiatría y Salud Mental (SEPSM); the Fundació Vila Saborit; the Societat Catalana de Psiquiatria i Salut Mental (SCPiSM); and the Translational Research Programme for Brain Disorders, IDIBAPS. IG has received support from the Spanish Ministry of Science, Innovation and Universities (MCIN) (PI23/00822) integrated into the Plan Nacional de I+D+I and cofinanced by the ISCIII-Subdirección General de Evaluación and European Union (FEDER, FSE, Next Generation EU/Plan de Recuperación Transformación y Resiliencia_PRTR); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); and Generalitat de Catalunya and Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2021 SGR 01128), CERCA Programme / Generalitat de Catalunya as well as the Fundació Clínic per la Recerca Biomèdica (Pons Bartran 2022-FRCB_PB1_2022)., Peer reviewed